<DOC>
	<DOCNO>NCT03024255</DOCNO>
	<brief_summary>This study conduct assess safety efficacy 3 concentration BBI-4000 vehicle ( 4 treatment arm ) , apply treatment axillary hyperhidrosis .</brief_summary>
	<brief_title>A Confirmatory Safety Efficacy Study BBI-4000 Subjects With Axillary Hyperhidrosis</brief_title>
	<detailed_description>This Multicenter , Randomized , Double Blind , Vehicle-Controlled Study Evaluate Safety Efficacy 3 concentration Topically Applied BBI-4000 Subjects Axillary Hyperhidrosis . Safety assess collection vital sign , adverse event , local skin response , hematology , serum chemistry laboratory test urinalysis .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Male female subject ≥ 18 year age . Diagnosis primary axillary hyperhidrosis meet follow criterion : ( ) symptoms hyperhydrosis least 6 month ' duration , ( b ) HDSMAx 3 4 , ( c ) HDSS 3 4 ( ) minimum GSP 50 mg axilla combine total least 150 mg . The ability understand follow studyrelated procedure include study drug administration . Sexually active female childbearing potential ( FOCBP ) * must agree periodic pregnancy test use medically acceptable method contraception receive protocolassigned product . In Investigators opinion , skin subcutaneous tissue condition axilla ( ) . Prior use prohibit medication ( ) procedure ( ) within specify timeframe treatment axillary hyperhidrosis . Anticholinergic agent use treat condition , limit , hyperhidrosis , asthma , incontinence , gastrointestinal cramp , muscular spasm route administration . Use potent inhibitor cytochrome P450 CYP3A CYP2D6 . Use cholinergic drug ( e.g . bethanechol ) within 30 day . Known cause hyperhidrosis know history condition may cause hyperhidrosis ( i.e. , hyperhidrosis secondary know cause hyperthyroidism , diabetes mellitus , medication , etc. ) . Subjects unstable diabetes mellitus thyroid disease , history renal hepatic impairment , malignancy glaucoma , intestinal obstructive motility disease , obstructive uropathy , myasthenia gravis , BPH , neurological psychiatric condition , Sjögren 's Sicca syndrome , cardiac abnormality may alter exacerbate sweat production use anticholinergic investigator 's opinion . Subjects know hypersensitivity glycopyrrolate , anticholinergic , component topical formulation . Subject pregnant , lactate plan become pregnant study . History presence supraventricular tachycardia , ventricular arrhythmia , atrial fibrillation atrial flutter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sweat gland disease</keyword>
	<keyword>sweat</keyword>
	<keyword>underarm</keyword>
</DOC>